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Abstract
Borrelia burgdorferi sensu lato is the causative agent of Lyme
borreliosis in humans. This inflammatory disease can affect the
skin, the peripheral and central nervous system, the musculo-
skeletal and cardiovascular system and rarely the eyes. Early
stages are directly associated with viable bacteria at the site of
inflammation. The pathogen–host interaction is complex and has
been elucidated only in part. B. burgdorferi is highly susceptible to
antibiotic treatment and the majority of patients profit from this
treatment. Some patients develop chronic persistent disease
despite repeated antibiotics. Whether this is a sequel of pathogen
persistence or a status of chronic auto-inflammation, auto-immunity
or a form of fibromyalgia is highly debated. Since vaccination is not
available, prevention of a tick bite or chemoprophylaxis is
important. If the infection is manifest, then treatment strategies
should target not only the pathogen by using antibiotics but also
the chronic inflammation by using anti-inflammatory drugs.
Introduction
In recent decades much has been learned about the aetiology
of Borrelia burgdorferi infection and the transmitting arthropod,
the tick. The exact pathogenesis, however, especially of late-
stage manifestations of Lyme disease, is far from clear. Several
models of disease pathogenesis and the treatment options are
being debated controversially. This debate is reflected in a
significant uncertainty of how to treat long-term manifestations
of the disease in particular. The authors of the present review
have tried to summarise what is known about disease
aetiology, pathogenesis and treatment from these different
perspectives in order to provide a basis for future discussions.
Clinical disease and pathogenesis of Lyme
disease
Borrelia species, the transmitting vectors and early skin
manifestations
Lyme borreliosis in adults has been divided into three clinical
stages [1,2]. The early manifestations of the infection mainly
involve the skin and the nervous system. At the site of the tick
bite an erythema migrans regularly develops, but can be
absent in up to 20 to 50% of patients [3] depending on the
region of the reports. The skin lesion is infrequently accom-
panied by unspecific symptoms of a systemic infection,
including malaise, fatigue, headache, fever and regional
lymphadenopathy.
In the USA, erythema migrans seems to be present more
regularly than in Europe; it has been associated with a
comparably more intense inflammation and a systemic spread
of the pathogen, which might reflect that in the USA only one
species of B. burgdorferi sensu lato – namely B. burgdorferi
sensu strictu – is responsible, whereas in Europe further
species – Borrelia afzelii and Borrelia garinii, and recently
Borrelia spielmanii [4,5] – have been identified. Another early
skin manifestation, Borrelia lymphocytoma (lymphadenosis
cutis benigna) – a purple nodular lesion affecting the ear, the
nose or the breast nipple – has only been reported in
European patients [6]. This may again reflect the presence of
different regional Borrelia genotypes and/or strains.
Despite these differences in aetiology, the clinical manifes-
tations are otherwise quite comparable. A few weeks to
months after the pathogen has been transferred from the
vector, especially Ixodes ticks, to the human host, several
organs may become affected, probably because of a
haematogenous spread of the pathogen. The arthropod
vector differs geographically. In Europe Ixodes ricinus is
transmitting the pathogen, whereas in America the trans-
mitting species is Ixodes scapularis.
Early dissemination of the pathogen
The next phase of disease is denominated early dissemina-
tion. A systemic disease evolving out of a single erythema
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migrans lesion has been reported in up to 40% of affected
children. About 25% of children with rare multiple erythema
migrans do have cerebrospinal fluid (CSF) pleocytosis,
demonstrating a clinically nonovert dissemination of the
pathogen into the central nervous system (CNS) [7].
Aside from this systemic dissemination into the skin, early
dissemination mainly affects the nervous system – presenting
as meningitis (CSF pleocytosis) and cranial neuritis predomi-
nantly in children. Meningoradiculoneuritis (Bannwarth’s syn-
drome) and plexus neuritis are reported less frequently. The
involvement of the heart was documented as atrioventricular
blockade, myopericarditis and cardiomyopathy, but seems to
be rare in both Europe and North America [8]. Early
musculoskeletal complaints are reported frequently in the
United States, and are less frequent in Europe. The
musculoskeletal system can be involved with mild arthralgia
and myalgia, in addition to a mild oligoarthritis.
In children, early dissemination and especially neuroborreliosis
usually occurs earlier than in adults. This might be due to a
different site of the tick bite. In children the upper trunk and
the head are selected more often by the tick than in adults,
potentially making the CNS more accessible to the
spirochete [9].
Late stages of Lyme disease
The late stages of disease appearing months to years after
infection are somewhat comparable between children and
adults. In children, however, the affection of the skin and CNS
are rarely seen [10]. Episodic or chronic oligoarthritis is the
most frequent manifestation [11]. Neurological manifesta-
tions, more frequent in adulthood (polyneuropathy, encepha-
lomyelitis, cranial neuropathy), are hardly recognised in
children [12]. Rarely, uveitis and keratitis have been reported
as late manifestations [13]. Among untreated patients in the
USA, around 60% begin to have intermittent attacks of joint
swelling and pain. The knees and other large joints are
especially affected [1,14]. Synovial inflammation/arthritis
usually is nonerosive, but can be erosive with cartilage and
joint destruction – especially with chronic, persistent
antibiotic-refractory arthritis. Left untreated, arthritis does
show a prolonged course with a gradual, spontaneous
resolution after several (up to 6) years [11]. Late skin mani-
festations have long been described as Acrodermatitis
chronica atrophicans. Of interest, this condition has only
been reported occasionally in adolescents.
Strategies proven to be effective in the treatment of Lyme
borreliosis in one geographic location are often extrapolated
to other regions in which the Borrelia species may differ and
predominant clinical manifestations may vary. Because the
natural history of untreated Lyme borreliosis is not delineated
for all regions, it is difficult to assess whether these treatment
regimens are equally efficacious across geographic regions
without additional controlled studies. In addition, other tick-
transmitted infections, such as babesiosis, human granulo-
cytic ehrlichiosis and southern tick-associated rash illness,
may complicate the diagnosis and treatment response,
especially in the case of coinfections [15,16].
Some patients treated with antibiotics for Lyme arthritis do
not experience a resolution of their arthritis, even after more
than one course of treatment. The pathogenesis of this
condition is not elucidated. Several hypotheses exist.
Antibiotic-treatment-refractory Lyme arthritis might be rooted
in a persistent infection of the pathogen suggested by the
presence of borrelial DNA [17], retained spirochetal antigens
with no living bacteria present [18], a pathogen-induced
autoimmunity resulting from a T-cell-receptor epitope mimicry
[19-21] or, finally, a nonspecific bystander immune activation.
In individual patients, a predefined rheumatological auto-
immunity might be unmasked by borrelial infection. In this
regard, a predominance of HLA alleles DR4 and DRB1 has
been associated both with chronic Lyme arthritis and adult
rheumatoid arthritis in the USA [1]. In Europe, however, such
an HLA association has not been elicited in affected adults
and children [22,23].
The concept of molecular mimicry was suggested several
years ago by identification of leukocyte function associated
antigen 1 alpha as a candidate auto-antigen, which might
cross-react with an outer surface protein A peptide epitope in
treatment-refractory Lyme arthritis patients who express
HLA-DRB1*0401 [19,21]. This concept would suggest a
reactive type of arthritis being present in Lyme disease. Of
particular interest is the capability of the pathogen to interact
with the human immune system. At first, the innate immune
system is capable of detecting the infection [24]. Sequentially
the adaptive immune system is attacking the pathogen by
B. burgdorferi-specific antibodies targeting various outer
surface and structural proteins. B. burgdorferi is capable,
however, of eliciting a variety of survival strategies inside the
human host in order to circumvent the innate and the
adaptive immune system. These strategies include comple-
ment resistance, antigen variation, lateral gene transfer and
lipoprotein polymorphism [25]. In addition, the pathogen itself
may be able to persist inside human phagocytic or tissue
resident cells in vitro [25,26]. In the human organism,
however, such a long-term persistence seems to be, if
present at all, a very rare event, even though it has been
suggested by some occasional case reports [27,28]. It is of
interest, however, in patients with chronic treatment-refrac-
tory arthritis that B. burgdorferi DNA has been detected in
synovial tissue, but not in synovial fluid samples even after
repetitive antibiotic treatments [17]. Whether this reflects the
actual presence of a viable pathogen is unclear at the
moment, but is controversially debated [29].
Morphological changes of B. burgdorferi into the shape of
cystic structures have been described in experimental
environmental conditions. Again, whether this is of relevancein vivo has not been elucidated [30]. In a recent detailed
structural analysis of brain tissue samples spirochetal or
cystic structures have been reported in patients affected by
neuroborreliosis. Control tissue of chronic brain inflammation
other than borreliosis was not provided, however, limiting the
evaluation of these findings [31].
There certainly is a consensus that an antibiotic treatment is
of relevance in every different stage of Lyme borreliosis. What
is the basis for this consensus and are there needs for a
treatment beyond that?
Current treatment of Lyme disease
Prevention of Lyme borreliosis
Prevention of Lyme borreliosis after a tick bite has been
reported using a single dose of doxycycline as chemoprophy-
laxis in America [32]. In Europe, however, a comparable
prophylactic treatment has not been evaluated with regard to
I. ricinus tick bites. The best prophylactic strategy is to avoid
a tick bite. A rapid removal of a tick within 6 hours (I. ricinus)
to 24 hours (I. scapularis) has been suggested [33]. The use
of protective clothing and of tick repellents is advised, but this
is beyond the scope of the present review.
Treatment of early manifestations
Early descriptions from America suggested that an erythema
migrans can resolve spontaneously within 6 weeks, but an
antibiotic treatment can shorten its duration to a few days
[34]. Since then treatment studies have no longer included a
placebo arm. Antibiotic treatment using doxycycline, amoxi-
cillin, penicillin, cefuroxime axetil, ceftriaxone and recently
azithromycin was focused on the outcome. In particular, an
equal effectiveness in avoiding late manifestations has been
shown by treatment of erythema migrans with doxycycline,
amoxicillin and cefuroxime axetil for 14 days (Table 1) [35].
Oral antibiotics seem to be a sufficient treatment for solitary
erythema migrans without signs of systemic disease.
Extending the treatment with doxycycline from 10 to 20 days
or adding an additional dose of ceftriaxone at the beginning
did not improve the therapeutic efficacy in patients with
erythema migrans [36]. A subsequent late stage of Lyme
disease can therefore be prevented effectively by treating
erythema migrans with antibiotics [37]. Since doxycycline can
only be used in childhood starting at the age of 8 years and
because of frequent allergies involving penicillin derivatives,
azithromycin has been evaluated for the treatment of early
Lyme disease. Owing to the longer half-life, treatment
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Table 1
Antibiotic therapy for early Borrelia burgdorferi infection
Early manifestations (days to a few weeks after the tick bite)
General symptoms Influenza-like disease ￿ Amoxicillin 50 mg/kg/day in three divided doses (maximum dose 1,500 mg/day)
￿ Doxycycline 4 mg/kg/day in two divided doses (maximum 200 mg/day; after 
8 years of age)
for 14 days
Skin Erythema migrans ￿ Amoxicillin 50 mg/kg/day in three divided doses (maximum dose 1,500 mg/day)
￿ Cefuroxime axetil 20 to 30 mg/kg/day in two divided doses (maximum dose 
1,000 mg/day)
￿ Doxycycline 4 mg/kg/day in two divided doses (maximum 200 mg/day; 
after 8 years of age)
for 14 days or
Lymphocytoma for 28 days
Neurologic disease Lymphocytic meningitis  ￿ Intravenous ceftriaxone 50 mg/kg/day in one dose 
(maximum dose 2,000 mg/day)
Cranial neuritis, in  ￿ Intravenous cefotaxime 200 mg/kg/day in three divided doses 
particular facial nerve (maximum dose 6,000 mg/day)
Cardiac disease Myopericarditis ￿ Intravenous penicillin G 0.5 million U/kg/day in four to six divided doses 
(maximum 20 million U/day)
for 14 days
￿ Doxycycline 4 mg/kg/day in two divided doses (maximum 200 mg/day; 
after 8 years of age)
for 14 to 28 days
Eye Conjunctivitis (in case of  ￿ Amoxicillin 50 mg/kg/day in three divided doses (maximum dose 1,500 mg/day)
influenza-like disease)
Joint, muscle Arthralgia ￿ Doxycycline 4 mg/kg/day in two divided doses (maximum 200 mg/day; 
after 8 years of age)
for 14 daysduration has been limited to 5 days. Even though Massarotti
and colleagues found azithromycin to be equally effective for
the treatment of early Lyme disease [38], Luft and colleagues
considered azithromycin to be inferior when compared with
amoxicillin [39].
Overall, antibiotic treatment studies in Europe did reveal
results comparable with the US examinations. Erythema
migrans takes somewhat longer to resolve, however, which
has been associated with the presence of three different
Borrelia species in Europe [6,40].
About 25 to 70% of patients with erythema migrans develop
nonspecific symptoms including fatigue, headache, arthralgia
and myalgia, fever and lymphadenopathy, suggesting a
systemic dissemination of the pathogen. In America this early
dissemination is reflected in part by the presence of multiple
annular skin lesions, a rare phenomenon in Central Europe. In
patients with acute disseminated Lyme disease (excluding
patients with meningitis, but with an erythema migrans
present, in addition to signs of disease dissemination), oral
doxycycline for 21 days was equally as effective in preventing
late manifestations of disease as intravenous ceftriaxone for
14 days [41]. Wormser suggested that erythema migrans
with uncomplicated facial nerve palsy can be treated with a
14-day course of antibiotic treatment using oral doxycycline,
amoxicillin or cefuroxime in adulthood [35]. If a significant
heart involvement or meningitis is present with erythema
migrans, however, an intravenous antibiotic treatment regi-
men using ceftriaxone or cefotaxime was recommended for
14 days [35].
In paediatric patients the response to first-line treatment has
been comparable with that of adults. Oral amoxicillin has
been shown to be as effective as cefuroxime axetil [42]. In
addition, phenoxymethylpenicillin has been shown to be
effective in solitary erythema migrans [43]. The use of
doxycycline after the age of 8 years has been considered
reasonable in early stages of Lyme disease also in children.
Most patients treated for early cutaneous Lyme borreliosis
have an excellent prognosis, although some patients treated
for erythema migrans continue to have a variety of complaints
after antibiotic therapy in recent series. Coinfection with
infectious agents other than B. burgdorferi has been
considered in this regard [44]. Coinfection in general,
however, seems to be a rare event even in populations at high
risk – it cannot be regarded as a general phenomenon
[45,46]. There are no data that chronic Lyme borreliosis is
associated with coinfections.
Early B. burgdorferi dissemination
In the second phase of infection about 15% of patients
develop an acute neuroborreliosis a few weeks to months
after the tick bite. Typical symptoms are cranial neuritis
including Bell’s palsy, meningitis and radiculitis. They are
caused by meningeal inflammation, which can be
accompanied by a significant headache or pain radiating into
the extremities. The clinical picture of the second stage
seems comparable throughout the world. In children, how-
ever, lymphocytic pleocytosis and facial nerve palsy seem to
be much more common than radiculitis [47]. There are
sufficient treatment reports to conclude that infection of the
nervous system in both adults and children can be treated
with penicillin, ceftriaxone and cefotaxime intravenously as
well as doxycycline orally (Table 2). Although parenteral
treatment regimens for neuroborreliosis are generally pre-
ferred, several European studies support the use of oral
doxycycline with a noncomplicated CNS involvement [48].
In very rare cases, encephalomyelitis – and especially
transverse myelitis – has been reported in childhood [12]. An
intravenous antibiotic treatment for 14 days was effective in
treating these children. Since CNS involvement in children
can occur quite early (within a few days) after a tick bite, a
previously  Borrelia-nonexposed host might not be able to
mount a detectable antibody response against the pathogen
in such a short time [49]. Pleocytosis or facial palsy due to
Borrelia might therefore not be distinguishable from other
infectious causes like Mycoplasma or herpes virus infections,
because serology can be unremarkable [49]. At this time, the
physician might consider an additional macrolide antibiotic or
antiviral treatment, especially if there are no signs of improve-
ment during antimicrobial treatment with β-lactams [50].
In addition, corticosteroids have been recommended in Bell’s
palsy [50]. The authors have not found reports that cortico-
steroid treatment proved harmful in patients with Bell’s palsy
who were diagnosed with Lyme disease subsequently.
Nevertheless, the usage of corticosteroids in patients with
facial paralysis and highly suspected Lyme aetiology cannot
be recommended and has to be considered with caution. The
long-term outcome of noncomplicated neuroborreliosis (facial
paralysis or pleocytosis) seems to be quite good, with minor
residual facial palsies in up to 20% of patients. Cerebro-
vascular neuroborreliosis with signs of vasculitis and cerebral
ischemia has rarely been reported in children [51].
Late stages of Lyme disease
Arthritis
In the early days of therapeutic approaches in Lyme arthritis,
only very few studies have been performed in which a fraction
of patients was left untreated or was treated with placebo.
These patients seemed to have a prolonged course of
arthritis when compared with the antibiotic-treated (penicillin
or ceftriaxone) patients [11]. Nontreated patients with Lyme
arthritis have been reported to suffer from ongoing chronic or
episodic arthritis, or progress to other late manifestations
including keratitis and chronic encephalopathy [52].
Some indirect evidence has been gathered that antibiotic
treatment is indeed targeting a persistent infection: patients
Arthritis Research & Therapy    Vol 11 No 6 Girschick et al.
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antibody titres to B. burgdorferi, whereas antibody titres
remained high in patients who were left untreated. Patients
who presented with persistent arthritis despite antibiotic
treatment also showed a decline in antibody titres. This
suggested that synovial inflammation persisted in these
patients after the infection was cleared by the use of
antibiotics [53]. The studies conducted, however, have not
tried to evaluate a principal anti-inflammatory effect of anti-
biotics. Steere and Angelis reported on their initial, untreated
Lyme arthritis cohort. Arthritis eventually resolved after a
disease duration of about 6 years or longer in children,
adolescents and adults [11]. In the author’s own experience,
however, there are a few patients who eventually continue to
have chronic arthritis despite several antibiotic treatments
according to European guidelines [54]. In these patients,
local inflammation stays active and significant antirheumatic
treatment strategies are necessary. Which particular patient
does not benefit from antibiotic treatment and who is prone
to proceed to long-term Lyme arthritis is not clear. As already
mentioned, immunological features, genetic factors and
pathogen-related factors might all contribute to the evolution
into a rheumatoid-like disease. Even though a significant
portion of treatment-refractory patients with Lyme arthritis has
been noted in several studies, the general consensus is that
antibiotic treatment remains the cornerstone of therapy
[11,40].
Steere and Angelis recently formulated a treatment algorithm
for the diagnosis and treatment of Lyme arthritis. As an initial
treatment they suggest using oral doxycycline or oral
amoxicillin for 30 days. They proposed a repetition of the oral
antibiotic regimen for another 30 days if a mild arthritis
persists after the first-line treatment was completed 30 days
ago. An intravenous antibiotic treatment using ceftriaxone,
cefotaxime or penicillin for 30 days was recommended if a
moderate to severe arthritis persists. The basis for this
suggestion, especially the reason for the prolongation of
treatment up to 30 days, was not made clear. This suggestion
has to be considered an expert opinion [11]. In comparison,
other authors have reported that penicillin G is not as
effective as ceftriaxone for the treatment of late Lyme
manifestations [55].
Significant side effects using an intravenous treatment
strategy for longer than 14 days have to be considered. The
authors of the present review suggested a repetition of
antibiotic therapy in antibiotic-refractory Lyme arthritis for the
duration of 14 days with a preference of using intravenous
cefotaxime in an inpatient setting (three divided doses) [54].
Cefotaxime seems to have lesser side effects than ceftriaxone
with regard to complications of bile secretion.
In an outpatient setting, intravenous ceftriaxone for the dura-
tion of 14 days would be the first choice (one daily dose).
Reviewing the work of Steere and Angelis, a significantly
greater number of doxycycline-treated patients (45 out of 71)
did respond to therapy when compared with five out of 46
patients who responded after intravenous ceftriaxone. This
remarkable failure rate using ceftriaxone as a first-line agent
was left unexplained [11]. For children older than 8 years of
age, arthritis can be treated using doxycycline in a dose of
4 mg/kg/day [54] (Fig. 1). From a rheumatological point of
view, it is striking that in almost all of the Lyme arthritis
studies reported, no concomitant anti-inflammatory therapy
has been evaluated. Our experience is that the parallel usage
of nonsteroidal anti-inflammatory drugs right from the
beginning does reduce symptoms of inflammation and
contributes to a faster resolution of arthritis, even though no
prospective long-term data are available.
In children and adolescents, treatment guidelines in Europe
do include the usage of nonsteroidal anti-inflammatory drugs
in parallel to antibiotics. There was a consensus that the
second round of antibiotic treatment should not exceed a
time period of 14 days with intravenous antibiotics or 4 weeks
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Table 2
Therapy for late stages of Borrelia burgdorferi infection or inflammation
Late stages of Lyme disease (months to years after the tick bite)
Skin Acrodermatitis chronica  ￿ Intravenous cefotaxime 50 mg/kg/day in one dose (maximum dose 
atrophicans 2,000  mg/day)
Neurologic disease Meningoradiculoneuritis ￿ Intravenous cefotaxime 200 mg/kg/day in three divided doses (maximum dose 
6,000 mg/day)
Encephalomyelitis  ￿ Intravenous penicillin G 0.5 million U/kg/day in four to six divided doses 
(maximum 20 million U/day)
Heart Cardiomyopathy  for 14 days
Eye Uveitis, keratitis ￿ Doxycycline 4 mg/kg/day in two divided doses (maximum 200 mg/day; 
after 8 years of age)
Joint, muscle Episodic or chronic  for 28 days
oligoarthritis For arthritis, add a nonsteroidal anti-inflammatory drugwith oral doxycycline [54]. If arthritis persists after two
complete courses of antibiotic treatment and sufficient non-
steroidal anti-inflammatory drug treatment, intra-articular
steroids and the use of disease-modifying antirheumatic
drugs should be considered [54]. Arthroscopic synovectomy
has been reported occasionally [11]. A further prolongation of
the antibiotic treatment was suggested in case the synovial
fluid or tissue analysis does reveal the presence of
B. burgdorferi DNA. This suggestion can be considered of
expert level and is not based on controlled studies [11]. It is
not clear whether such a positive PCR represents the
presence of a viable pathogen or simply nondegraded DNA,
and whether this finding is of clinical relevance.
A prospective treatment study was reported from a European
childhood cohort in 1995 [23]. The response rate after one
or two courses of different antibiotics resulted in a dis-
appearance of arthritis in 77% of the patients [56]. Szer and
colleagues reported on the long-term follow-up of patients
initially followed by Steere and colleagues who were not
treated with antibiotics. Only a few patients were reported to
suffer from ongoing chronic or episodic arthritis, or progress
to other late manifestations including keratitis and chronic
encephalopathy [52]. The scarcity of the studies on long-term
outcome does reflect an urgent need to perform follow-up
studies even on a retrospective basis. In addition, a long-term
prospective controlled trial is warranted in order to further
elucidate the beneficial role of antibiotics in children. It seems
reasonable to consider conventional anti-inflammatory drug
treatment for arthritis already from the start together with
antibiotics.
Late neurological disease
Peripheral polyneuropathy (paresthesia), meningoradiculo-
neuritis (radicular pain), encephalopathy (memory loss, mood
changes, sleep disturbance) or encephalomyelitis do repre-
sent late neurological manifestations in adulthood [57]. Treat-
ment efforts using antibiotics (Table 3) usually are effective
[57]. In childhood, neurological disease is predominantly an
early manifestation (CSF pleocytosis, facial palsy) but also
can present as radiculitis in older children [58]. Late
manifestations have to be considered very rare.
Late skin disease
Late skin manifestations are usually caused by B. garinii and
B. afzelii, and are thus seen predominantly in Europe and not
in the USA. Acrodermatitis chronica atrophicans is caused by
B. afzelii and is characterised as a blue/red-coloured atrophic
skin lesion predominantly at the extremities [59]. Antibiotic
therapy for at least 4 weeks has been recommended
(Table 3) [60].
Post-Lyme disease syndrome
Despite the resolution of Lyme borreliosis manifestations after
antibiotic treatment in the majority of patients, a minority of
patients present fatigue, musculoskeletal pain, concentration
or short-term memory problems. These generally mild and
self-limiting symptoms have been termed post-Lyme disease
symptoms. If the symptoms last longer than 6 months they
have been called post-Lyme disease syndrome.
In contrast to the late manifestations of antibiotic-refractory
arthritis and post-Lyme disease symptoms/syndrome, there is
a group of patients with chronic pain, neurocognitive
symptoms, fatigue, and so forth. In some of these patients the
diagnosis of chronic Lyme disease has been made without
clinical or serological evidence of a current or previous Lyme
disease. There have been attempts to define the patho-
genesis of this particular complex of symptoms. Not yet
standardised diagnostic tests to detect B. burgdorferi
immunoreactivity have often been implemented. Recent
studies, which have tried to define these patients more
clearly, in general point towards other causative differential
diagnoses including fibromyalgia or other autoimmune
musculoskeletal diseases [61-63]. Intravenous or oral
antibiotics for a prolonged period of time or repetitively did
not improve symptoms in these particular patients [61].
Nevertheless there is still a major controversy in the literature
and in the press requesting long-term antibiotic treatment for
these patients [29,64].
To make things difficult, a few arthritis patients have been
described with evidence that B. burgdorferi DNA persisted in
the joint without anti-B. burgdorferi antibodies present in their
peripheral blood [65]. The cause of seronegativity is
unknown. One possible cause might be the formation of
immune complexes involving antigen-specific antibodies.
Since routine serodiagnostic tests rely on free antibodies,
antibodies tied up in complexes would not be detectable
[66]. In the majority of patients suffering from late Lyme
disease, however, a robust antibody response is present.
There might be only very few individuals affected by Lyme
arthritis or post-Lyme disease syndrome who do not have a
detectable serological response to the pathogen. Sero-
negative patients without clinical signs of classical Lyme
disease but with chronic fatigue, arthralgia and myalgia did
not respond to antibiotics even when multiple courses of
treatments were given. This study was also interpreted in a
way that serological tests can reliably rule out Lyme
borreliosis in patients with these chronic symptoms, thus
preventing unnecessary treatment with antibiotics [67]. For
the majority of chronic Lyme disease patients, other differen-
tial diagnoses should be considered. This could avoid long-
term, and therefore potentially side-effect-prone, antibiotic
treatment. As can be expected, there is a lot of controversy
on the subject of chronic Lyme disease [29,62,68].
Strategies to generate a vaccine against
Borrelia
Several significant obstacles have to be overcome before a
vaccine can be considered effective in the context of the
complex tick–host–pathogen interaction in Lyme borreliosis.
Arthritis Research & Therapy    Vol 11 No 6 Girschick et al.
Page 6 of 10
(page number not for citation purposes)B. burgdorferi is able to mount molecular survival strategies in
order to circumvent the host’s immune defence mechanisms
[25]. In addition, persistence in bradytrophic tissues might
render the pathogen inaccessible for the immune system [27].
B. burgdorferi not only manipulates human resident tissue
cells and members of the immune system, but also interacts
with the gene expression profile of the tick vector. The latter
strategy enables the pathogen to survive within the tick and
during the transmission process. Some of these tick gene
products might be potentially valuable in developing a vector-
antigen-based vaccine [69]. These vector-based vaccine
targets, however, are just at the beginning of being evaluated.
In the early 1990s, the major outer-surface protein (Osp) A
and OspB were already considered interesting targets for a
pathogen-based vaccine [70]. Since only one B. burgdorferi
genotype is present in the United States, two recombinant
OspA vaccine preparations were eventually tested in adults
as well as in children – the vaccines were considered safe
and their immunogenicity to be sufficient to mount an anti-
OspA immune response [71]. It was of particular immuno-
logical interest that the recombinant OspA vaccine was able
to block transmission of the spirochete from the vector to the
host by virtually sterilising the infected vector. During the
blood feast, OspA-specific antibodies were transferred from
the immunised host to the vector. These transferred
antibodies did interfere with the complex lifecycle of the
spirochetes, which express OspA especially inside the tick.
Success of the vaccine in murine animal models [72] was the
basis for these human studies [73]. Subsequent analyses of
the cost-effectiveness revealed that individuals who live in
areas where Lyme disease is endemic and who are frequently
exposed to ticks are the best candidates to be vaccinated
[74]. Despite clinical effectiveness and no significant side
effects reported, Lyme disease vaccines have been taken off
the market or are no longer propagated. Fears that an OspA-
based vaccine could itself induce an autoimmune disease by
induction of a cross-reactive immune response might have
contributed to low sales of the vaccine and its final
withdrawal from the market.
Owing to the presence of several Borrelia genotypes in
Europe, a monovalent vaccine is not considered effective
throughout Europe. Different vaccine targets therefore have
to be considered. In addition, due to molecular strategies of
the Lyme disease spirochete B. burgdorferi, including anti-
genic variation and immune escape, complement resistance
as well as lateral gene transfer, one particular preventive
strategy seems insufficient to induce long-term protection [25].
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Table 3
Therapy for persistent Lyme arthritis refractory to the first antibiotic treatment
Persistent Lyme arthritis
Antibiotic-refractory Significant  inflammation  Repeat
persistent arthritis (effusion, limited range of 
motion, oligoarthritis)
￿ Intravenous cefotaxime 50 mg/kg/day in one dose 
(maximum dose 2,000 mg/day)
￿ Intravenous cefotaxime 200 mg/kg/day in three divided doses 
(maximum dose 6,000 mg/day)
￿ Intravenous penicillin G 0.5 million U/kg/day in four to six divided doses 
(maximum 20 million U/day)
for 14 days up to 28 days
Limited inflammation  ￿ Doxycycline 4 mg/kg/day in two divided doses (maximum 200 mg/day; 
(for example, monoarthritis) after 8 years of age)
for 28 days
Additional anti-inflammatory therapy: nonsteroidal anti-inflammatory drugs 
No remission reached In synovial fluid or synovia: Prolong antibiotic oral treatment for another month
B. burgdorferi DNA present Consider 
￿ Intra-articular steroid injection 
￿ Disease-modifying antirheumatic drug therapy 
￿ Arthroscopic synovectomy
B. burgdorferi DNA not present Consider 
￿ Intra-articular steroid injection 
￿ Disease-modifying antirheumatic drug therapy 
￿ Arthroscopic synovectomyConclusion
Even though Lyme borreliosis is considered an infection, and
despite high antibiotic sensitivity of the pathogen, a limited
number of patients treated for late-stage disease remain
symptomatic despite antibiotics. The reason for persistent
symptoms is unclear. Several pathogen-related and host-
related factors have been suggested. There is considerable
lack of knowledge on the natural course of disease in
different environments and with regard to different genotypes
or even strains of B. burgdorferi sensu lato. Coinfections may
complicate the picture even further.
Current knowledge of the effectiveness of antibiotic treatment
strategies is based on a very limited number of trials, which
have not been evaluated sufficiently long term and which often
lack a placebo-controlled arm. In addition, the number of
patients included has to be considered limited, as no large
double-blind, controlled, long-term prospective trials have
been performed. Unsurprising, therefore, is the considerable
uncertainty of which antibiotic regimen should be chosen and
which duration of therapy should be performed. For the time
being, guidelines for antibiotic treatment have been suggested
that are successful in about 80% of patients affected by late
stages of B. burgdorferi infections.
Overall, the outcome of early and late manifestations seems
to be good; nevertheless, there is an urgent need to develop
strategies for those patients who do not respond completely
to the current treatment concepts.
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